García-Sánchez, Ainhoa
Sotolongo-Grau, Oscar
Tartari, Juan Pablo
Sanabria, Ángela
Esteban - De Antonio, Ester
Pérez-Cordón, Alba
Alegret, Montserrat
Pytel, Vanesa
Martínez, Joan
Aguilera, Núria
de Rojas, Itziar
Cano, Amanda
García-González, Pablo
Puerta, Raquel
Olivé, Clàudia
Capdevila, Maria
García-Gutiérrez, Fernando
Vivas, Assumpta
Gómez-Chiari, Marta
Giménez, Juan
Tejero, Miguel Ángel
Castilla-Martí, Miguel
Castilla-Martí, Luis
Tárraga, Lluís
Valero, Sergi
Ruiz, Agustín
Boada, Mercè
Marquié, Marta
Alllué, J. A.
Appiani, F.
Ariton, D. M.
Berthier, M.
Bojayrin, U.
Buendia, M.
Bullich, S.
Campos, F.
Castillo, S.
Cañabate, P.
Cañada, L.
Cuevas, C.
Diego, S.
Espinosa, A.
Gailhajenet, A.
Guitart, M.
Ibarria, M.
Lafuente, A.
Lleonart, N.
Lomeña, F.
Martín, E.
Moreno, M.
Morera, A.
Montrreal, L.
Niñerola, A.
Nogales, A. B.
Núñez, L.
Orellana, A.
Ortega, G.
Páez, A.
Pancho, A.
Pelejà, E.
Pérez-Martínez, E.
Pérez-Grijalba, V.
Pascual-Lucas, M.
Perissinotti, A.
Preckler, S.
Ricciardi, M.
Roé-Vellvé, N.
Romero, J.
Ramis, M. I.
Rosende-Roca, M.
Sarasa, M.
Seguer, S.
Stephens, A. W.
Terencio, J.
Torres, M.
Vargas, L.
Appiani, F.
Ariton, D. M.
Bojayrin, U.
Buendía, M.
Calvet, A.
Castillón, M. J.
Cañabate, P.
Cañada, L.
Cuevas, C.
de Rojas, I.
Diego, S.
Espinosa, A.
Gailhajenet, A.
Guitart, M.
Ibarria, M.
Lafuente, A.
Lleonart, N.
Martín, E.
Moreno, M.
Morera, A.
Montrreal, L.
Nogales, A. B.
Orellana, A.
Ortega, G.
Pancho, A.
Preckler, S.
Ricciardi, M.
Ramis, M. I.
Rosende-Roca, M.
Seguer, S.
Vargas, L.
,
,
Funding for this research was provided by:
Instituto de Salud Carlos III (FI20/00215, CD22/00125, AC17/00100, PI17/01474, PI19/00335)
Ministerio de Ciencia e Innovación, Proyectos de Generación de Conocimiento, Spain (PID2021-122473OA-I00)
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CNV-304-PRF-866)
EU Joint Programme – Neurodegenerative Disease Research (AC19/00097)
Article History
Received: 8 May 2023
Accepted: 4 February 2024
First Online: 20 February 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. The FACEHBI-2 protocol (which includes study v5) and BIOFACE protocol were approved by the Ethics Committee of Hospital Clínic i Provincial in Barcelona, Spain. Informed consent was obtained from all participants involved in the study.
: Not applicable.
: MB has consulted for Araclon, Avid, Grifols, Lilly, Nutricia, Roche, Eisai and Servier. She received fees from lectures and funds for research from Araclon, Biogen, Grifols, Nutricia, Roche and Servier. She reports grants/research funding from Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, S.A, Merck Sharp & Dohme, Kyowa Hakko Kirin, Laboratorios Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, Roche Pharma SA, and Schwabe Farma Iberica SLU, all outside the submitted work. She has not received personal compensations from these organizations. AR is member of scientific advisory board of Landsteiner Genmed and Grifols SA. AR has stocks of Landsteiner Genmed. MM has consulted for F. Hoffmann-La Roche Ltd. The rest of authors declare that they have no competing interests.